Recruiting NA INTERVENTIONAL 2-arm NCT06265350

Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases

Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases: A Single-center, Prospective, Randomized Controlled Phase II Study

Sponsor: Sun Yat-sen University

Conditions Bevacizumab Cadonilimab Cryoablation Hepatocellular Carcinoma Liver Cancer Stage IV Pulmonary Metastases

Interventions Bevacizumab Cadonilimab Cryoablation

Updated 3 times since 2024 Last updated: Feb 9, 2024 Started: Feb 2, 2024 Primary completion: Jan 30, 2026 Completion: Jan 30, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Bevacizumab and Cadonilimab and is currently actively recruiting participants. Sun Yat-sen University leads this study, which shows 3 recorded versions since 2024 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Recruiting NA
Jul 2024 — Sep 2024 [monthly]

Recruiting NA
Mar 2024 — Jul 2024 [monthly]

Recruiting NA

First recorded

Feb 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sun Yat-sen University

Data source: Sun Yat-sen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guanzhou, China